News

Darolutamide Prolongs OS in Metastatic, Hormone-Sensitive Prostate Cancer: Results From the ARASENS Trial

04/14/2022

John Otrompke

Study findings suggest darolutamide added to ADT and docetaxel significantly reduces risk of death among patients with metastatic, hormone-sensitive prostate cancer compared to treatment with ADT and docetaxel alone.

Study findings suggest...

04/14/2022

Oncology

News

Immune Checkpoint Inhibitors vs Chemotherapy for Metastatic, Castration-Resistant Prostate Cancer

04/14/2022

John Otrompke

Among patients with metastatic, castration-resistant prostate cancer and high tumor mutational burden, treatment with immune checkpoint inhibitors is associated with improved outcomes compared to treatment with taxanes.

Among patients with metastatic,...

04/14/2022

Oncology

News

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan and Companion Diagnostic Agent for Metastatic, Castration-Resistant Prostate Cancer

04/14/2022

John Otrompke

The FDA approved lutetium Lu 177 vipivotide tetraxetan and a companion diagnostic agent for PSMA–positive, metastatic, castration-resistant prostate cancer previously treated with an androgen receptor inhibitor and taxane-based chemotherapy.

The FDA approved lutetium Lu 177...

04/14/2022

Oncology

Conference Coverage

Next Steps in PARP Inhibitor Targeted Approaches for Prostate Cancer: Single Agents and Combinations

03/30/2022

Janelle Bradley

In a presentation at the 2022 Great Debates and Updates in Genitourinary Oncology meeting, Maha Hussain, MD, FACP, FASCO, discussed PARP inhibitor targeted approaches for metastatic castration-resistant prostate cancer.

In a presentation at the 2022...

03/30/2022

Oncology

Conference Coverage

Evolving Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer

03/30/2022

Janelle Bradley

In a presentation at the 2022 Great Debates and Updates in Genitourinary Oncology meeting, Oliver Sartor, MD, discussed the evolving treatment landscape for metastatic hormone-sensitive prostate cancer.

In a presentation at the 2022...

03/30/2022

Oncology

News

Optimal Period of ADT May Vary Depending on Receipt of Brachytherapy in High-Risk Prostate Cancer

03/30/2022

John Otrompke

The optimal minimum duration of ADT may be less than 18 months for high-risk prostate cancer patients receiving external beam radiation therapy (EBRT) plus brachytherapy, but more than 18 months for patients receiving EBRT alone.

The optimal minimum duration of...

03/30/2022

Oncology

News

First-Line Abiraterone Associated With Differential Outcomes by Race in mCR Prostate Cancer

02/24/2022

First-line abiraterone is found associated with improved overall survival among African American men compared with non-Hispanic White men with metastatic castration-resistant prostate cancer.

First-line abiraterone is found...

02/24/2022

Oncology

News

FDA Approves AI-Based Software for Screening Assistance in Prostate Cancer

09/24/2021

The FDA has approved marketing of an AI software that will assist in the detection of cancer, as an adjunct to the review of digitally scanned slide images from prostate biopsies.

The FDA has approved marketing...

09/24/2021

Oncology

News

Safety, Efficacy of PSMA-Targeting Agent Being Assessed in mCRPC

07/26/2021

Investigators behind the phase 3 SPLASH trial are evaluating the safety and efficacy of 177Lu-PNT2002 for patients with mCRPC.

Investigators behind the phase 3...

07/26/2021

Oncology

News

FDA Authorizes Study of 2 Novel Treatments for Patients With PSMA+ mCRPC

07/26/2021

Researchers receive FDA authorization to evaluate 2 novel PSMA theranostic treatments, for patients with mCRPC.

Researchers receive FDA...

07/26/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology